advanced search

EXPERT VIEW

SUSTAINABILITY AND DRUG DELIVERY DEVICES
EXPERT VIEW
Rob Veasey
SUSTAINABILITY AND DRUG DELIVERY DEVICES
Rob Veasey explores the environmental challenges facing the drug delivery device industry – and the opportunities they bring.
WEARABLE INJECTORS: LATEST DEVICES & RECENT TRENDS
EXPERT VIEW
Tom Oakley
WEARABLE INJECTORS: LATEST DEVICES & RECENT TRENDS
Wearable injection device expert Tom Oakley discusses recent trends in the space. He also takes a look at wearable injection devices currently on the market and considers the future of wearable injectors.
ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE
EXPERT VIEW
Frédérique Bordes-Picard
ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE
Frédérique Bordes-Picard  and Julien Lamps discuss the value of capsule-based dry powder inhalers in the modern respiratory market, the factors driving development in this area and considerations for matching a capsule to a device and formulation.
THE RISE OF COMPLEX ORAL DELIVERY SYSTEMS
EXPERT VIEW
María FM Balson
THE RISE OF COMPLEX ORAL DELIVERY SYSTEMS
María Fernández-Martos Balson and Bastiaan De Leeuw explore the oral delivery of biologics and the challenges that must be overcome in order to enhance bioavailability. The authors also take a look at some recently developed drug-device combinations.
COVID-19: A CATALYST FOR IMPLEMENTING CONNECTED HEALTHCARE PRODUCTS?
EXPERT VIEW
Napoleon Monroe
COVID-19: A CATALYST FOR IMPLEMENTING CONNECTED HEALTHCARE PRODUCTS?
Napoleon Monroe analyses how covid-19 is catalysing a wide range of reactions in healthcare, explaining how drug and device connectivity are essential to improving patient access to treatment – and patient outcomes – as well as reducing overall cost. 
RISKS AND REAL-WORLD SOLUTIONS FOR CONNECTED MEDICAL DEVICES
EXPERT VIEW
Tom Oakley
RISKS AND REAL-WORLD SOLUTIONS FOR CONNECTED MEDICAL DEVICES
Tom Oakley discusses the risks surrounding the use of connected drug delivery devices – and the real-world solutions that have either been proved or are being trialled.
CONNECTED DEVICE DATA NEEDED TO MAKE HOME CARE THE STANDARD
EXPERT VIEW
Dr Andrei Yosef
CONNECTED DEVICE DATA NEEDED TO MAKE HOME CARE THE STANDARD
With home care on the increase as a result of the coronavirus pandemic, Andrei Yosef looks at the crucial role played by connected home care medical devices and the data they generate.
SENSOR ADVANCEMENTS IN DRUG DELIVERY IMPROVE COMPLIANCE
EXPERT VIEW
Salvatore Forte
SENSOR ADVANCEMENTS IN DRUG DELIVERY IMPROVE COMPLIANCE
Salvatore Forte discusses various advancements in sensors that are transforming drug delivery systems, making complex devices more automated, easier to use, and improving patient compliance as a result.
WHICH IS THE BETTER TOXICITY TESTING STRATEGY FOR COMBINATION DEVICES?
EXPERT VIEW
Mark Turner
WHICH IS THE BETTER TOXICITY TESTING STRATEGY FOR COMBINATION DEVICES?
Mark Turner explores the issue of toxicity testing for combination devices and asks which is the better testing strategy – ISO 10993 or extractables and leachables?
DESIGN CONSIDERATIONS FOR IMPROVING TRAINING DEVICE SAFETY AND EFFECTIVENESS
EXPERT VIEW
Yvonne Limpens
DESIGN CONSIDERATIONS FOR IMPROVING TRAINING DEVICE SAFETY AND EFFECTIVENESS
Yvonne Limpens and Brenda van Geel, explore the design considerations that need to be taken into account when developing training devices that are safe and effective – and support patients in learning how to administer an injection correctly.
EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?
EXPERT VIEW
Beth Crandall
EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?
With the compliance deadline for the EU Medical Device Regulation recently delayed by a year due to the novel coronavirus pandemic, Beth Crandall looks at what it means for the medical device industry.
SILICA RE-EMERGES AS POTENTIAL NUCLEIC ACID DELIVERY VECTOR
EXPERT VIEW
Nigel Theobald
SILICA RE-EMERGES AS POTENTIAL NUCLEIC ACID DELIVERY VECTOR
Nigel Theobald looks at the challenges of oligonucleotide delivery and explores approaches to overcome them.
RESPIRATORY DRUG DELIVERY: THEN, NOW AND SOON
EXPERT VIEW
Brennan Miles
RESPIRATORY DRUG DELIVERY: THEN, NOW AND SOON
Brennan Miles takes a look back at respiratory drug delivery over the last few decades to see what we can learn from the past – and looks ahead to what the future might look like, covering sustainability, device regulation, and formulation milestones.
PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS
EXPERT VIEW
Dr Igor Gonda
PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS
Igor Gonda, David Cipolla and Philippe Rogueda discuss the changes needed to increase the number of approved generic orally inhaled drug products (OIDPs) whilst providing additional incentives to innovators to meet the needs of the general public.
THE OPTIONS FOR CREATING A MORE SUSTAINABLE INHALER
EXPERT VIEW
Phil Seeney
THE OPTIONS FOR CREATING A MORE SUSTAINABLE INHALER
With growing pressure to tackle climate change, Phil Seeney looks at the arguments in favour of creating more sustainable inhalers, and examines potential strategies to accomplish it.
CHOOSING THE RIGHT LABEL MATERIAL FOR PREFILLED SYRINGES
EXPERT VIEW
Jos van Noort
CHOOSING THE RIGHT LABEL MATERIAL FOR PREFILLED SYRINGES
Jos van Noort outlines some of the key factors that must be taken into consideration when selecting a label for prefillable syringes.
EU MDR: ANCILLARY DELIVERY DEVICES FACE EQUAL SCRUTINY TO STANDALONE MEDICAL DEVICES
EXPERT VIEW
Elizma Parry
EU MDR: ANCILLARY DELIVERY DEVICES FACE EQUAL SCRUTINY TO STANDALONE MEDICAL DEVICES
Elizma Parry offers her expertise and practical guidance to businesses hoping to achieve a CE mark for a medical device, with new EU regulations being implemented this year.
PREFILLED SAFETY SYRINGE MARKET THRIVES AMID SELF-ADMINISTRATION TREND
EXPERT VIEW
George I’ons
PREFILLED SAFETY SYRINGE MARKET THRIVES AMID SELF-ADMINISTRATION TREND
George I’ons looks at how the growing trend of patient self-administration is driving demand for prefilled safety syringes.
LARGE-VOLUME INJECTORS: RISE IN BIOLOGICS BRINGS CHALLENGES
EXPERT VIEW
Dr Paolo Fiorini
LARGE-VOLUME INJECTORS: RISE IN BIOLOGICS BRINGS CHALLENGES
Developing devices capable of delivering highly viscous biologic drug formulations at high volumes does not come without its challenges. Paolo Fiorini, Gerard Linnane, Michael Kiely, Maciej Grygorczuk and Joshua Coyne discuss these challenges and the merits of various drive solutions.
HOW TO DESIGN A BODY-WORN INJECTOR
EXPERT VIEW
Steve Augustyn
HOW TO DESIGN A BODY-WORN INJECTOR
Body-worn injectors require you to understand your user, your drug and your technology – and there are numerous pitfalls for the unwary. Stephen Augustyn shares some insights.
OPTIMISING OPHTHALMIC DRUG DELIVERY FOR THERAPEUTIC EFFECTIVENESS
EXPERT VIEW
Dr Barbara Morgan
OPTIMISING OPHTHALMIC DRUG DELIVERY FOR THERAPEUTIC EFFECTIVENESS
Barbara Morgan discusses how eye physiology impacts product formulation and choice of dosage form, and how advanced delivery technologies are providing new options for formulators seeking to improve the bioavailability or stability of their ophthalmic treatments.
TRANSFORMING HEALTHCARE – HOW CURATIVE THERAPIES WILL DISRUPT THE MARKET
EXPERT VIEW
Dr Ulrica Sehlstedt
TRANSFORMING HEALTHCARE – HOW CURATIVE THERAPIES WILL DISRUPT THE MARKET
Ulrica Sehlstedt, Craig Wylie, Thomas Unger, Rebecka Axelsson Wadman, Vikas Kharbanda, and Satoshi Ohara, all members of Arthur D. Little’s Healthcare and Life Sciences Practice, explain how the shift to curative treatments promises to transform the entire healthcare ecosystem. 
CHOOSING THE RIGHT CONNECTIVITY FOR DRUG DELIVERY AND MEDICAL PRODUCTS
EXPERT VIEW
Dr Juan Nogueira
CHOOSING THE RIGHT CONNECTIVITY FOR DRUG DELIVERY AND MEDICAL PRODUCTS
Juan Nogueira; Tommaso Borghi and Marco Vergani discuss the factors that need to be taken into account in the selection of connectivity technology for a drug delivery device or other medical product.
HOW A DIGITAL APPROACH CAN UNPICK CLINICAL TRIAL CHALLENGES AND IMPROVE OUTCOMES
EXPERT VIEW
Dr Matt Ash
HOW A DIGITAL APPROACH CAN UNPICK CLINICAL TRIAL CHALLENGES AND IMPROVE OUTCOMES
Matt Ash, Tom Lawrie-Fussey and Bastiaan De Leeuw look at the role digital technology can play in the development of drug-device combination products.
Top